Bristol-Myers Squibb Company (BMY)
Return on total capital
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) (ttm) | US$ in thousands | -20,004,000 | -14,471,000 | -9,531,000 | -4,556,000 | 9,591,000 | 9,751,000 | 9,846,000 | 9,972,000 | 8,927,000 | 8,958,000 | 8,931,000 | 8,545,000 | 9,412,000 | -2,865,000 | -2,747,000 | -2,645,000 | -5,471,000 | 4,779,000 | 3,727,000 | 3,640,000 |
| Long-term debt | US$ in thousands | 47,603,000 | 48,674,000 | 48,858,000 | 49,487,000 | 36,653,000 | 32,137,000 | 34,656,000 | 35,078,000 | 35,056,000 | 36,966,000 | 37,107,000 | 37,450,000 | 39,605,000 | 39,677,000 | 42,503,000 | 44,505,000 | 48,336,000 | 41,364,000 | 41,853,000 | 42,844,000 |
| Total stockholders’ equity | US$ in thousands | 16,335,000 | 17,142,000 | 17,015,000 | 16,490,000 | 29,430,000 | 28,998,000 | 31,973,000 | 31,824,000 | 31,061,000 | 32,671,000 | 32,600,000 | 31,580,000 | 35,946,000 | 37,213,000 | 36,808,000 | 37,605,000 | 37,822,000 | 50,158,000 | 49,094,000 | 49,911,000 |
| Return on total capital | -31.29% | -21.99% | -14.47% | -6.91% | 14.51% | 15.95% | 14.78% | 14.91% | 13.50% | 12.86% | 12.81% | 12.38% | 12.46% | -3.73% | -3.46% | -3.22% | -6.35% | 5.22% | 4.10% | 3.92% |
December 31, 2024 calculation
Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $-20,004,000K ÷ ($47,603,000K + $16,335,000K)
= -31.29%
Bristol-Myers Squibb Company's return on total capital has shown fluctuations over the period of analysis, ranging from positive to negative values. The return on total capital increased from 3.92% in March 2020 to a peak of 15.95% in September 2023. However, there was a significant decline in the return on total capital in the latter part of the period, with negative returns starting in March 2024 and declining further to -31.29% by December 2024.
These fluctuations indicate a volatile performance in terms of generating returns on the capital invested in the company. Investors and stakeholders may need to closely monitor the company's financial performance and management of capital to understand the factors contributing to the fluctuations in the return on total capital.
Peer comparison
Dec 31, 2024